Status:
TERMINATED
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Eligibility:
All Genders
45-70 years
Phase:
PHASE1
PHASE2
Brief Summary
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
Eligibility Criteria
Inclusion
- Histologically-confirmed intestinal GC (T2-T4)
- Local or locally advanced stage II or stage III gastric cancer of an upper part of the stomach or GE junction
- Lymph node positive or negative
- Metastasis negative
- Resection with curative intent (R0, D2)
- Chemo- and radiotherapy naïve
- Measurable lesion according RECIST
- Written informed consent
Exclusion
- Aged below 45 or over 70
- Prior gastric surgery
- Active ILD
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2004
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00237900
Start Date
July 1 2003
End Date
February 1 2004
Last Update
April 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Reseach Site
Helsinki, Finland